Protein Arginine Methyltransferase 5 (PRMT5) Inhibitors in Oncology Clinical Trials: A review

por Feustel, Kavanya, Falchook, Gerald S.
Publicado 2022

Dabrafenib for treatment of BRAF-mutant melanoma

por Kainthla, Radhika, Kim, Kevin B, Falchook, Gerald S
Publicado 2013

Bromodomain and Extra-Terminal (BET) Domain Protein Inhibitors for Solid Tumor Cancers

por Nguyen, Martin V., Loof, Lydia, Falchook, Gerald S.
Publicado 2020

DCVax®- DIRECT: autologous activated dendritic cells for image guided intra-tumoral vaccination in patients with solid tumors - a phase I/II clinical trial in progress

por Subbiah, Vivek, Murthy, Ravi, Hosing, Chitra, Kaur, Indresh, Falchook, Gerald, Bosch, Marnix
Publicado 2013

A phase 2 trial of trifluridine/tipiracil plus nivolumab in patients with heavily pretreated microsatellite‐stable metastatic colorectal cancer

por Patel, Manish R., Falchook, Gerald S., Hamada, Kensuke, Makris, Lukas, Bendell, Johanna C.
Publicado 2021

Responses of metastatic basal cell and cutaneous squamous cell carcinomas to anti-PD1 monoclonal antibody REGN2810

por Falchook, Gerald S., Leidner, Rom, Stankevich, Elizabeth, Piening, Brian, Bifulco, Carlo, Lowy, Israel, Fury, Matthew G.
Publicado 2016

Phase I dose-escalating study of TAS-106 in combination with carboplatin in patients with solid tumors

por Naing, Aung, Fu, Siqing, Zinner, Ralph G., Wheler, Jennifer J., Hong, David S., Arakawa, Kazuhito, Falchook, Gerald S., Kurzrock, Razelle
Publicado 2013

BRAF Mutations in Advanced Cancers: Clinical Characteristics and Outcomes

por El-Osta, Hazem, Falchook, Gerald, Tsimberidou, Apostolia, Hong, David, Naing, Aung, Kim, Kevin, Wen, Sijin, Janku, Filip, Kurzrock, Razelle
Publicado 2011

Phase I, first-in-human trial of programmed cell death receptor-1 (PD-1) inhibitor, JTX-4014, in adult patients with advanced, refractory, solid tumors

por Papadopoulos, Kyriakos P., Lakhani, Nehal, Falchook, Gerald S., Riley, Gosia, Baeck, Johan, Brown, Karen S., Gordon, Gilad, Le, Lidya, Wang, Judy S.
Publicado 2020

Older adults in phase I clinical trials: a comparative analysis of participation and clinical benefit rate among older adults versus middle age and AYA patients on phase I clinical...

por Subbiah, Ishwaria M., Tang, Chad, Rao, Arvind, Falchook, Gerald S., Subbiah, Vivek, Tsimberidou, Apostolia M., Karp, Daniel, Kurzrock, Razelle, Hong, David S.
Publicado 2018

Translational pharmacokinetic‐pharmacodynamic modeling of preclinical and clinical data of the oral MET inhibitor tepotinib to determine the recommended phase II dose

por Xiong, Wenyuan, Friese‐Hamim, Manja, Johne, Andreas, Stroh, Christopher, Klevesath, Manfred, Falchook, Gerald S., Hong, David S., Girard, Pascal, El Bawab, Samer
Publicado 2021

Phase I study of the investigational oral mTORC1/2 inhibitor sapanisertib (TAK-228): tolerability and food effects of a milled formulation in patients with advanced solid tumours

por Moore, Kathleen N, Bauer, Todd M, Falchook, Gerald S, Chowdhury, Swapan, Patel, Chirag, Neuwirth, Rachel, Enke, Aaron, Zohren, Fabian, Patel, Manish R
Publicado 2018

A phase Ib study of adavosertib, a selective Wee1 inhibitor, in patients with locally advanced or metastatic solid tumors

por Falchook, Gerald S, Sachdev, Jasgit, Imedio, Esteban Rodrigo, Kumar, Sanjeev, Mugundu, Ganesh M, Jenkins, Suzanne, Chmielecki, Juliann, Jones, Suzanne, Spigel, David R, Johnson, Melissa
Publicado 2023

PIK3CA Mutations Frequently Coexist with RAS and BRAF Mutations in Patients with Advanced Cancers

por Janku, Filip, Lee, J. Jack, Tsimberidou, Apostolia M., Hong, David S., Naing, Aung, Falchook, Gerald S., Fu, Siqing, Luthra, Rajyalakshmi, Garrido-Laguna, Ignacio, Kurzrock, Razelle
Publicado 2011

Next generation sequencing of exceptional responders with BRAF-mutant melanoma: implications for sensitivity and resistance

por Wheler, Jennifer, Yelensky, Roman, Falchook, Gerald, Kim, Kevin B, Hwu, Patrick, Tsimberidou, Apostolia M, Stephens, Philip J, Hong, David, Cronin, Maureen T, Kurzrock, Razelle
Publicado 2015

Advanced gynecologic malignancies treated with a combination of the VEGF inhibitor bevacizumab and the mTOR inhibitor temsirolimus

por Piha-Paul, Sarina A., Wheler, Jennifer J., Fu, Siqing, Levenback, Charles, Lu, Karen, Falchook, Gerald S., Naing, Aung, Hong, David S., Tsimberidou, Apostolia M., Kurzrock, Razelle
Publicado 2014

KRASness and PIK3CAness in Patients with Advanced Colorectal Cancer: Outcome after Treatment with Early-Phase Trials with Targeted Pathway Inhibitors

por Garrido-Laguna, Ignacio, Hong, David S., Janku, Filip, Nguyen, Ly M., Falchook, Gerald S., Fu, Siqing, Wheler, Jenifer J., Luthra, Rajyalakshmi, Naing, Aung, Wang, Xuemei, Kurzrock, Razelle
Publicado 2012

Effect of Food on the Pharmacokinetics of the Investigational Aurora A Kinase Inhibitor Alisertib (MLN8237) in Patients with Advanced Solid Tumors

por Falchook, Gerald S., Zhou, Xiaofei, Venkatakrishnan, Karthik, Kurzrock, Razelle, Mahalingam, Devalingam, Goldman, Jonathan W., Jung, JungAh, Ullmann, Claudio Dansky, Milch, Catherine, Rosen, Lee S., Sarantopoulos, John
Publicado 2015

Pharmacokinetics of ixazomib, an oral proteasome inhibitor, in solid tumour patients with moderate or severe hepatic impairment

por Gupta, Neeraj, Hanley, Michael J., Venkatakrishnan, Karthik, Perez, Raymond, Norris, Robin E., Nemunaitis, John, Yang, Huyuan, Qian, Mark G., Falchook, Gerald, Labotka, Richard, Fu, Siqing
Publicado 2016

A dose escalation/expansion study evaluating dose, safety, and efficacy of the novel tyrosine kinase inhibitor surufatinib, which inhibits VEGFR 1, 2, & 3, FGFR 1, and CSF1R, in US...

por Dasari, Arvind, Hamilton, Erika P., Falchook, Gerald S., Wang, Judy S., Li, Daneng, Sung, Max W., Chien, Caly, Nanda, Shivani, Tucci, Christopher, Hahka-Kemppinen, Marjo, Paulson, Andrew Scott
Publicado 2023